Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Ifetroban

Generic Name: Ifetroban

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₂N_₂O_₅

CAS Number: 143443-90-7

Unique Ingredient Identifier: E833KT807K

Overview

Ifetroban has been used in trials studying the treatment of Skin Diseases, Autoimmune Diseases, Pathologic Processes, Scleroderma, Limited, and Scleroderma, Diffuse, among others.

Background

Ifetroban has been used in trials studying the treatment of Skin Diseases, Autoimmune Diseases, Pathologic Processes, Scleroderma, Limited, and Scleroderma, Diffuse, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Recruiting

Posted: 2022/10/07

Sponsor:

Cumberland Pharmaceu...

ID:NCT05571059

Thromboxane Receptor Antagonist to Improve Endothelial Function

Phase 2

Completed

Posted: 2019/05/24

Sponsor:

Jeffrey Rade

ID:NCT03962855

Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

Phase 2

Active, not recruiting

Posted: 2018/10/03

Sponsor:Vanderbilt-Ingram Ca...

ID:NCT03694249

Oral Ifetroban in Subjects with Duchenne Muscular Dystrophy

Phase 2

Active, not recruiting

Posted: 2017/11/13

Sponsor:

Cumberland Pharmaceu...

ID:NCT03340675

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban

Phase 2

Completed

Posted: 2017/10/30

Sponsor:Brigham and Women's ...

ID:NCT03326063

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Cumberland Pharmaceuticals Reports Breakthrough in DMD Treatment and 11.6% Q4 Revenue Growth

3 months ago

Cumberland Pharmaceuticals achieved positive Phase II results for ifetroban in treating cardiac complications of Duchenne muscular dystrophy, marking the first successful study of its kind.

Qureight's AI Imaging Platform to Support Avalyn's Inhaled Pirfenidone Trial in Pulmonary Fibrosis

4 months ago

Qureight and Avalyn Pharma have formed a strategic partnership to integrate deep-learning imaging technology in the Phase 2b MIST trial evaluating inhaled pirfenidone (AP01) for progressive pulmonary fibrosis.

Solid Biosciences' SGT-003 Gene Therapy Shows Promise in Duchenne Muscular Dystrophy Trial

4 months ago

Solid Biosciences reported positive initial data from its Phase 1/2 INSPIRE DUCHENNE trial of SGT-003, a gene therapy candidate for Duchenne muscular dystrophy (DMD).

FDA Approves Simplified Dosing Regimen for Acetadote in Acetaminophen Overdose

5 months ago

The FDA has approved a supplemental New Drug Application (sNDA) for Acetadote, used to prevent liver damage following acetaminophen overdose.

Cumberland Pharma Reports Key Clinical and Business Developments in November 2024

6 months ago

Cumberland Pharma has announced significant milestones in November 2024, including new research findings, expanded Medicaid coverage, and product access improvements. Highlights include favorable outcomes for Caldolor® compared to ketorolac, FDA designations for Ifetroban targeting Duchenne Muscular Dystrophy, advancements in delirium treatment, and efforts to combat antimicrobial resistance with Vibativ®.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy